Clinical Outcomes and Tumor Immune Microenvironment in Epstein–Barr Virus-Positive Gastroesophageal Adenocarcinoma Treated with Immune Checkpoint Inhibitors
Epstein–Barr virus-positive gastroesophageal adenocarcinoma (EBV-GEA) is a distinct molecular subtype characterized by recurrent genomic and epigenetic alterations, frequent PD-L1/PD-L2 upregulation, and an immune-enriched tumor microenvironment. These features provide a strong biological rationale for immune checkpoin...